Antibodies to citrullinated proteins: Pathogenic and diagnostic significance

被引：6

作者：

Holers V.M. ^{[1
]}

机构：

[1] Division of Rheumatology, Departments of Medicine and Immunology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045

来源：

Current Rheumatology Reports | 2007年 / 9卷 / 5期

关键词：

Rheumatoid Arthritis; Citrullinated; Shared Epitope; Epitope Spreading; Preclinical Animal Model;

D O I：

10.1007/s11926-007-0063-5

中图分类号：

学科分类号：

摘要：

The recent demonstration of efficacy in the treatment of rheumatoid arthritis with B-cell-depleting therapy, along with the increasing understanding of the role of anticitrullinated protein antibodies (ACPA) have begun to provide new insights into the pathogenesis of this complex disease. This manuscript reviews the current understanding of ACPA with regard to clinical associations and pathogenic mechanisms in preclinical animal models. These data are synthesized into a model of the development of rheumatoid arthritis that refocuses attention on the role of B cells and immune complexes, returning in part to the origins of scientific investigation in this disease, and points to directions of research that are necessary to achieve the full therapeutic, diagnostic, and prognostic potential of the ACPA antigen-antibody system. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：396 / 400

页数：4

共 32 条

[1]

Arend W.P., The innate immune system in rheumatoid arthritis, Arth Rheum, 44, pp. 2224-2234, (2001)

[2]

Toh M.L., Miossec P., The role of T cells in rheumatoid arthritis: New subsets and new targets, Cur Opin Rheum, 19, pp. 284-288, (2007)

[3]

Weyand C.M., New insights into the pathogenesis of rheumatoid arthritis, Rheumatology, 39, SUPPL. 1, pp. 3-8, (2000)

[4]

Zhang Z., Bridges S.L., Pathogenesis of rheumatoid arthritis. Role of B lymphocytes, Rheum Dis Clin North Am, 27, pp. 335-353, (2001)

[5]

Edwards J.C., Szczepanski L., Szechinski J., Et al., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Eng J Med, 350, pp. 2572-2581, (2004)

[6]

Edwards J.C., Cambridge G., Leandro M.J., B cell depletion therapy in rheumatic disease, Best Pract Res Clin Rheum, 20, pp. 915-928, (2006)

[7]

Monach P.A., Benoist C., Mathis D., The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease, Adv Immunol, 82, pp. 217-248, (2004)

[8]

Schrohenloher R.E., Bridget S.L., Koopman W.J., Rheumatoid factor, Arthritis and Allied Conditions: A Textbook of Rheumatology, pp. 1109-1130, (1997)

[9]

Schellekens G.A., de Jong B.A., van den Hoogen F.H., Et al., Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies, J Clin Invest, 101, pp. 273-281, (1998)

[10]

Masson-Bessiere C., Sebbag M., Girbal-Neuhauser E., Et al., The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the a- and b-chains of fibrin, J Immunol, 166, pp. 4177-4184, (2001)

← 1 2 3 4 →